CymaBay Therapeutics, Inc.
CIK 0001042074
Revenue (TTM)
$5.21M
+8.6% YoY
FY Jan 2024
Net Income (TTM)
−$87.97M
+0.6% YoY
FY Jan 2024
EPS Diluted (TTM)
−$0.90
+18.2% YoY
FY Jan 2024
Gross Margin
—
FY Jan 2024
Operating Margin
-1,546.8%
FY Jan 2024
Net Margin
-1,689.5%
FY Jan 2024
Free Cash Flow (TTM)
−$54.49M
FY Jan 2024
Cash
$206.54M
FY Jan 2024
Total Debt
—
FY Jan 2024
Shares Outstanding
114.72M sh
FY Jan 2024
Revenue & Net Income
EPS (Diluted)
Margins
Cash Flow
Revenue Growth (YoY)
No data available for this metric.